Abstract 399: CPTAC phase II final report

Abstract National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of robust, quantitative, proteomic technologies and workflows. The primary goal for this program is to systematically identify proteins that derive from alterations in cancer genomes and related biological processes, integrate the genomic and proteomic data from analysis of common cancer biospecimen and provide this data with accompanying assays and protocols to the community. The phase II effort managed by the Leidos Biomedical Research Inc. had a goal to procure and qualify a minimum of 100 cases from 3 cancer types (Breast, Ovarian and Colon). Tissues and analytes from the 100 cases were sent to proteomic and genomic characterization centers for analysis. The proteomic data were made available through the Data Coordinating Center (DCC) and the genomic data were made available through NCI’s Genomic Data Commons (GDC). The success from the phase II effort has set precedence for a much larger phase III effort that will focus on additional cancer types and cases. Preliminary analysis results confirm the need for the combination of the genomic and proteomic approaches to produce a more comprehensive inventory of the detectable proteins in a tumor and advance our understanding of cancer biology. Citation Format: Mathangi Thiagarajan. CPTAC phase II final report [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 399. doi:10.1158/1538-7445.AM2017-399